In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia.

Keywords

Neuroscience, Corticobasal degeneration, Dementia with Lewy bodies, Dopaminergic, Dopamine

References

• The neurochemistry of Alzheimer's disease.Paul T Francis — 1997
• Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone.縁 榎井 — 1993
• Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes.Linda Bäckman — 1997
• Dopamine transporter density measured by [123I]β‐CIT single‐photon emission computed tomography is normal in dopa‐responsive dystonia俊郎 山下 — 1998
• Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophyTienneke Saraswati — 2004
• Sleep microstructure and neurodegeneration as measured by [123I]β-CIT SPECT in treated patients with Parkinson’s diseaseSandra G. Catane, B Cabria Hillel, P Tomarong Cristituto — 2004
• Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degenerationEmmanuel Tonicello — 2006
• From tau to toxicity: Emerging roles of NMDA receptor in Alzheimer's diseaseA Cavallin — 2006
• Reduced 5-HT2A receptor binding in patients with mild cognitive impairment.Timothy D. Wells — 2008
• Neuropeptides in Alzheimer's disease.M. F. Beal, N. W. Kowall, M F Mazurek — 1987
• Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET.Hitoshi Shinotoh, Keizo Hirayama, Yukio Tateno — 1993
• Behandlung der Demenz bei Parkinson-SyndromenInga Liepelt, Walter Maetzler, Blaicher Hp — 2007
• [Evaluation of dopaminergic presynaptic function by [F-18] DOPA PET].Takashi Kato — 2007
• Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI.G. Arnold, Klaus Tatsch, Wolfgang H. Oertel — 1994
• Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.Thomas Brücke, S. Asenbaum, Walter Pirker — 1997
• Steele-Richardson-Olszewski-Syndrome: the relation of dopamine D2 receptor binding and subcortical lesions in MRIG. Arnold, Johannes Schwarz, Klaus Tatsch — 2002
• THE CENTENNIAL CELEBRATION OF LISTER'S BIRTH: THE BRITISH MEDICAL ASSOCIATION AT ITS ANNUAL MEETING, EDINBURGH, JULY 20, 1927George Herbert Rae Gibson — 1927
• Dementia in Parkinson's diseaseDag Aarsland, Mona K. Beyer, Martin Kurz — 2008
• New insight into the analysis of 6-[18F]fluoro-L-DOPA PET dynamic data in brain tissue without an irreversible compartment: comparative study of the Patlak and Logan analyses.Shoji Kawatsu, Takashi Kato, Atsuko Nagano‐Saito — 2003
• Frontotemporal dementia: therapeutic interventions.Mario F. Mendez — 2009

Cited by

• FROM REINFORCEMENT LEARNING MODELS OF THE BASAL GANGLIA TO THE PATHOPHYSIOLOGY OF PSYCHIATRIC AND NEUROLOGICAL DISORDERSAgus Hermawan — 2011
• Effects of l-DOPA on striatal iodine-123-FP-CIT binding and behavioral parameters in the ratŽeljko Rapanić — 2013
• Novel therapies for combating chronic neuropathological sequelae of TBI智子 渡邊, 真由美 石其, 緑 石渡 — 2018
• Electron microscopy of the mouse central nervous system.Wiebke Möbius, Benjamin H. Cooper, Walter A. Kaufmann — 2010
• Synaptic dysfunction in schizophrenia.Dong‐Min Yin, Yongjun Chen, Anupama Sathyamurthy — 2012
• Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian ratsJoanna L. Elson, Abi G. Yates, Ilse S. Pienaar — 2015
• Morphine and the canine brain : the influence of morphine on cerebral perfusion and 5-HT2A receptorsAntita Adriaens — 2013
• 18F-Fluorodeoxyglucamines: Reductive amination of hydrophilic 18F-fluoro-2-deoxyglucose with lipophilic amines for the development of potential PET imaging agentsAparna Baranwal, Jogeshwar Mukherjee — 2015
• Selective detection of dopamine in the presence of ascorbic acid via fluorescence quenching of InP/ZnS quantum dotsSeong Soo A. An, Jongsung Kim, Seshadri Reddy Ankireddy — 2015
• Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson’s diseaseAmélie C. Lanoue, Gene J. Blatt, Jean‐Jacques Soghomonian — 2013
• Focus on GABAA receptor functionHubertus Hautzel, H. W. Müller, Susanne Nikolaus — 2014
• Aripiprazole for Tourette's syndrome: a systematic review and meta‐analysisWei Zheng, Xianbin Li, Ying‐Qiang Xiang — 2016
• Dopamine and Oxytocin Interactions Underlying Behaviors: Potential Contributions to Behavioral DisordersTracey Baskerville, Alison J. Douglas — 2010
• Psychosis in Frontotemporal DementiaShunichiro Shinagawa, Shinichiro Nakajima, Eric Plitman — 2014
• Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson’s Disease?Walter Schulz‐Schaeffer — 2015
• In vivo imaging neurotransmitter functionRolf Larisch, H. Vosberg, Markus Beu — 2011
• Influencia da dupla-tarefa no equilibrio de pacientes com doença de Parkinson e demencia do tipo AlzheimerGustavo Christofoletti — 2010
• Low Serum Level α-Synuclein and Tau Protein in Autism Spectrum Disorder Compared to Controlsİhsan Çetin, Mahmut Cem Tarakçıoğlu, Ömer Faruk Özer — 2015
• Metabonomic studies of schizophrenia and psychotropic medications: focus on alterations in CNS energy homeostasis.Dan Ma, Paul C. Guest, Sabine Bahn — 2009
• Phenotypic Characterization of Retinoic Acid Differentiated SH-SY5Y Cells by Transcriptional ProfilingJoanna A. Korecka, Ronald E. van Kesteren, Eva Blaas — 2013

Related papers

• Clinical features of corticobasal degenerationE Ueno — 1996
• Progressive supranuclear palsy and corticobasal degeneration.Stephanie Lessig, Irene Litvan — 1997
• Intracellular processing of aggregated tau differs between corticobasal degeneration and progressive supranuclear palsyTetsuaki Arai, Kenji Ikeda, Haruhiko Akiyama — 2001
• Progressive supranuclear palsy and corticobasal degeneration: Diagnostic challenges and clinicopathological considerations.Alexandre Eusébio, Lejla Koric, Olivier Félician — 2016
• Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy.Paul Greene — 2019
• 類似した神経病理所見を呈する非定型的Progressive supranuclear palsy(PSP)とCorticobasal degeneration(CBD)について博史 名倉, 充秋 板東, 博 山之内 — 1997
• Progressive supranuclear palsy and corticobasal degeneration: Lumping versus splittingT. Scaravilli, Eduardo Tolosa, Isidró Ferrer — 2005
• Cardiac autonomic dysfunction in patients with progressive supranuclear palsy and corticobasal degenerationMasayuki Ochi, Hikari Ochi, Kensuke Senzaki — 2017